文献速递血栓与止血

福坦替尼在临床实践中治疗免疫性血小板减少症的有效性与安全性

Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice.
PubMed 文献 · Blood · 2024-01-01

这项西班牙42中心真实世界研究纳入138例原发性和继发性免疫性血小板减少症(ITP)患者,前瞻性和回顾性评估福坦替尼。中位年龄66岁,79%患者有效,53.6%获完全缓解,60.1%接受单药治疗者有效率达85.4%,48.5%发生不良事件,多为1-2级。

要点

  • 福坦替尼在真实世界ITP患者中有效率达79%,完全缓解率53.6%。
  • 单药治疗患者有效率达85.4%,中位起效时间11天。
  • 48.5%患者发生不良事件,最常见为腹泻和高血压,多为1-2级。

核心结论

  • 福坦替尼在广泛年龄范围的原发性和继发性ITP患者中显示出有效性和良好的安全性。

研究设计与样本

  • 西班牙42个中心的前瞻性和回顾性研究,纳入138例接受福坦替尼治疗的ITP患者(包括原发性和继发性),中位年龄66岁(IQR 56-80),女性占55.8%。

主要发现

  • 79%患者对福坦替尼有效,其中53.6%获完全缓解(血小板计数>100×10^9/L)。
  • 83例(60.1%)接受福坦替尼单药治疗,有效率达85.4%。
  • 在 examined 的27个月期间,处于缓解的时间比例为83.3%。
  • 中位血小板起效时间为11天(IQR 7-21)。
  • 67例(48.5%)发生不良事件,主要为1-2级,最常见为腹泻(n=28)和高血压(n=21);1例发生深静脉血栓,1例发生急性心肌梗死。

关键数值与推荐

  • 完全缓解定义为血小板计数>100×10^9/L。
  • 中位起病至福坦替尼启用时间为51个月(IQR 10-166),既往中位治疗线数为4(IQR 2-5)。
  • 58例(42.0%)在治疗开始前一个月有出血症状/体征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fostamatinib, a recently approved Syk inhibitor used in adult primary immune thrombocytopenia (ITP), has been shown to be safe and effective in this disorder. However, clinical trial results may not be similarly reproduced in clinical practice. Here, 138 patients with ITP (both primary and secondary) from 42 Spanish centers who had been treated with fostamatinib were evaluated prospectively and retrospectively. The median age of our cohort (55.8% women) was 66 years (interquartile range [IQR], 56-80). The median time since ITP diagnosis at fostamatinib initiation was 51 months (IQR, 10-166). The median number of therapies before fostamatinib initiation was 4 (IQR, 2-5), including eltrombopag (76.1%), romiplostim (57.2%), and IV immunoglobulins (44.2%). Fifty-eight patients (42.0%) had signs/symptoms of bleeding in the month before treatment initiation. Seventy-nine percent of patients responded to fostamatinib with 53.6% complete responses (platelet count > 100 × 109/L). Eighty-three patients (60.1%) received fostamatinib monotherapy, achieving a high response rate (85.4%). The proportion of time in response during the 27-month period examined was 83.3%. The median time to platelet response was 11 days (IQR, 7-21). Sixty-seven patients (48.5%) experienced adverse events, mainly grade 1 to 2; the commonest of which were diarrhea (n = 28) and hypertension (n = 21). One patient had deep venous thrombosis, and one patient developed acute myocardial infarction. Fostamatinib was shown to be effective with good safety profile in patients with primary and secondary ITP across a wide age spectrum in this real-world study.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. González-López TJ, Bermejo-Vega N, Cardesa-Cabrera R, et al. Fostamatinib effectiveness and safety for immune thrombocytopenia in clinical practice. Blood. 2024. PMID: 38843478. doi:10.1182/blood.2024024250

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。